Perrigo PE Ratio 2010-2024 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of January 21, 2025 is 9.57.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-17 | 23.84 | 0.00 | |
| 2024-09-30 | 25.98 | $-1.17 | 0.00 |
| 2024-06-30 | 25.20 | $-0.92 | 0.00 |
| 2024-03-31 | 31.58 | $-0.07 | 0.00 |
| 2023-12-31 | 31.28 | $-0.10 | 0.00 |
| 2023-09-30 | 30.78 | $0.05 | 615.64 |
| 2023-06-30 | 32.46 | $-0.42 | 0.00 |
| 2023-03-31 | 34.00 | $-0.96 | 0.00 |
| 2022-12-31 | 32.07 | $-0.96 | 0.00 |
| 2022-09-30 | 33.28 | $-0.63 | 0.00 |
| 2022-06-30 | 37.60 | $-0.70 | 0.00 |
| 2022-03-31 | 35.38 | $-0.65 | 0.00 |
| 2021-12-31 | 35.56 | $-1.92 | 0.00 |
| 2021-09-30 | 42.97 | $-3.29 | 0.00 |
| 2021-06-30 | 41.39 | $-2.41 | 0.00 |
| 2020-12-31 | 39.94 | $-1.21 | 0.00 |
| 2020-09-30 | 40.81 | $-0.06 | 0.00 |
| 2020-06-30 | 48.92 | $1.35 | 36.23 |
| 2020-03-31 | 42.39 | $1.58 | 26.83 |
| 2019-12-31 | 45.34 | $0.88 | 51.52 |
| 2021-03-31 | 36.35 | $1.49 | 24.40 |
| 2019-09-30 | 48.85 | $1.81 | 26.99 |
| 2019-06-30 | 41.44 | $0.65 | 63.75 |
| 2019-03-31 | 41.70 | $0.84 | 49.65 |
| 2018-12-31 | 33.42 | $0.94 | 35.56 |
| 2018-09-30 | 61.07 | $0.86 | 71.01 |
| 2018-06-30 | 62.73 | $1.66 | 37.79 |
| 2018-03-31 | 71.52 | $0.91 | 78.59 |
| 2017-12-31 | 74.62 | $0.84 | 88.83 |
| 2017-09-30 | 72.34 | $-9.16 | 0.00 |
| 2017-06-30 | 64.40 | $-18.23 | 0.00 |
| 2017-03-31 | 56.49 | $-16.39 | 0.00 |
| 2016-12-31 | 70.67 | $-19.23 | 0.00 |
| 2016-09-30 | 78.27 | $-10.49 | 0.00 |
| 2016-06-30 | 76.73 | $-0.96 | 0.00 |
| 2016-03-31 | 108.10 | $-2.98 | 0.00 |
| 2015-12-31 | 122.13 | $-0.13 | 0.00 |
| 2015-09-30 | 132.63 | $1.33 | 99.72 |
| 2015-03-31 | 139.43 | $0.56 | 248.98 |
| 2014-12-31 | 140.67 | $1.59 | 88.47 |
| 2014-09-30 | 126.31 | $0.21 | 601.45 |
| 2014-06-30 | 122.49 | $0.67 | 182.83 |
| 2014-03-31 | 129.87 | $0.67 | 193.84 |
| 2013-12-31 | 128.78 | $1.49 | 86.43 |
| 2013-09-30 | 103.48 | $3.48 | 29.74 |
| 2013-06-30 | 101.41 | $3.42 | 29.65 |
| 2013-03-31 | 99.44 | $3.42 | 29.07 |
| 2012-12-31 | 87.05 | $3.47 | 25.09 |
| 2012-09-30 | 97.12 | $3.41 | 28.48 |
| 2012-06-30 | 98.52 | $3.04 | 32.41 |
| 2012-03-31 | 86.24 | $3.04 | 28.37 |
| 2011-12-31 | 81.16 | $2.76 | 29.41 |
| 2011-09-30 | 80.93 | $2.67 | 30.31 |
| 2011-06-30 | 73.18 | $2.72 | 26.90 |
| 2011-03-31 | 66.17 | $2.72 | 24.33 |
| 2010-12-31 | 52.64 | $2.43 | 21.66 |
| 2010-09-30 | 53.32 | $2.01 | 26.53 |
| 2010-06-30 | 49.00 | $1.87 | 26.20 |
| 2010-03-31 | 48.65 | $1.87 | 26.02 |
| 2009-12-31 | 32.96 | $1.70 | 19.39 |
| 2009-09-30 | 28.08 | $1.53 | 18.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.252B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.826B | 25.11 |
| Stryker (SYK) | United States | $146.166B | 32.94 |
| Boston Scientific (BSX) | United States | $145.408B | 41.81 |
| EssilorLuxottica (ESLOY) | France | $115.383B | 0.00 |
| Medtronic (MDT) | Ireland | $112.944B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.849B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.827B | 27.18 |
| GE HealthCare Technologies (GEHC) | United States | $38.715B | 20.08 |
| ResMed (RMD) | United States | $35.199B | 28.92 |
| Terumo (TRUMY) | Japan | $27.980B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.250B | 18.56 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.811B | 13.89 |
| Insulet (PODD) | United States | $19.347B | 77.04 |
| Baxter (BAX) | United States | $15.818B | 10.29 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.057B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.586B | 32.58 |
| BellRing Brands (BRBR) | United States | $9.323B | 37.51 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.360B | 14.78 |
| ICU Medical (ICUI) | United States | $4.012B | 38.20 |
| Prestige Consumer Healthcare (PBH) | United States | $3.882B | 19.31 |
| Haemonetics (HAE) | United States | $3.691B | 18.01 |
| Envista Holdings (NVST) | United States | $3.413B | 25.42 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.807B | 18.07 |
| GN Store Nord (GNNDY) | Denmark | $2.585B | 16.58 |
| Neogen (NEOG) | United States | $2.508B | 28.90 |
| LeMaitre Vascular (LMAT) | United States | $2.227B | 54.13 |
| AtriCure (ATRC) | United States | $1.876B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.572B | 27.52 |
| AdaptHealth (AHCO) | United States | $1.416B | 10.11 |
| InMode (INMD) | Israel | $1.410B | 8.48 |
| BioLife Solutions (BLFS) | United States | $1.213B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.205B | 0.00 |
| Owens & Minor (OMI) | United States | $1.124B | 8.78 |
| Curaleaf Holdings (CURLF) | Canada | $0.981B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.843B | 14.87 |
| CeriBell (CBLL) | United States | $0.754B | 0.00 |
| Evolus (EOLS) | United States | $0.666B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.623B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.557B | 24.58 |
| Omeros (OMER) | United States | $0.541B | 0.00 |
| Surmodics (SRDX) | United States | $0.527B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.434B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.434B | 0.00 |
| ZimVie (ZIMV) | United States | $0.394B | 33.23 |
| Valneva SE (VALN) | France | $0.355B | 0.00 |
| Quanterix (QTRX) | United States | $0.342B | 0.00 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.18 |
| Biote (BTMD) | United States | $0.306B | 6.71 |
| Sanara MedTech (SMTI) | United States | $0.285B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.25 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.245B | 51.20 |
| Canopy Growth (CGC) | Canada | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.226B | 3.18 |
| Aurora Cannabis (ACB) | Canada | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.56 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| Brainsway (BWAY) | Israel | $0.192B | 102.30 |
| MacroGenics (MGNX) | United States | $0.188B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.168B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.77 |
| Veru (VERU) | United States | $0.143B | 0.00 |
| Jin Medical (ZJYL) | China | $0.143B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.130B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.87 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| INLIF (INLF) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.070B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.069B | 35.33 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.11 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |